Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Novel agents in development for the treatment of MCL

In this video, Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, shares some insights into novel agents being investigated for the treatment of mantle cell lymphoma (MCL). Dr Ghosh first comments on the promise of pirtobrutinib, which is currently being investigated in clinical trials. Dr Ghosh then discusses the promise of novel immunotherapies, including bispecifics, CAR-T therapy, and ROR1-targeting antibodies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche